|
ImClone Systems has one drug and it is making the most of it. The drug development company's only product on the market, Erbitux, is approved for treatment of colorectal cancer, as well as head and neck cancers. ImClone Systems co-promotes the drug with Bristol-Myers Squibb in North America and with Merck KGaA elsewhere. ImClone is continuing to develop Erbitux as a possible treatment for other kinds of cancer, including lung cancer. The company is also working on additional oncology-related antibody therapies. In 2008 ImClone was acquired by Eli Lilly for $6.5 billion, after rejecting bids from Bristol-Myers Squibb.
|
| | | Contact Information | |
Address: |
180 Varick St.
New York, NY 10014
| | Phone: | 212-645-1405 | | Fax: | 212-645-2054 |
|
| Financial
Highlights | | Fiscal Year End: | December |
|
|
Key People
| | • |
CEO:
John H. Johnson
| | • |
Media Relations:
Tracy Henrikson
| | • |
VP Commercial Operations:
Joseph I. DePinto
|
|
|
